Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASA404 with chemotherapy in advanced NSCLC
NCT00662597Phase 3Terminated
- Sponsor
- Novartis
- Start
- Apr 2008
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing ASA404 Arm with Placebo Arm (2 arms). Primary endpoint: Overall Survival Rate. Started Apr 2008; status: terminated.
02
Drugs
vadimezan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00662597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00662597.